Celsion Appoints Christine A. Pellizzari to its Board of Directors
09 juin 2021 08h00 HE
|
Celsion CORP
Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J., June 09, 2021 (GLOBE...
Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors
08 juin 2021 08h00 HE
|
Celsion CORP
25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez, MD LAWRENCEVILLE, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...
Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021
02 juin 2021 08h00 HE
|
Celsion CORP
Calls for All Shareholders to Vote so Quorum Requirement to Hold The Meeting is Met LAWRENCEVILLE, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021
27 mai 2021 08h30 HE
|
Celsion CORP
Calls for All Shareholders to Vote so Quorum Requirement to Hold The Meeting is Met LAWRENCEVILLE, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
Celsion Management Participates in Alliance Global Partners Virtual Series
22 avr. 2021 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Celsion Corporation Reports 2020 Financial Results and Provides Business Update
19 mars 2021 08h45 HE
|
Celsion CORP
Entered 2021 with a Focus on Cancer Immunotherapy and Next-Generation Infectious Vaccines and a Strong Balance Sheet Conference Call Begins at 11:00 a.m. Eastern Time Today ...
Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021
12 mars 2021 08h45 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores
25 févr. 2021 08h45 HE
|
Celsion CORP
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or...